Home Cart Sign in  
Chemical Structure| 870070-55-6 Chemical Structure| 870070-55-6

Structure of Tozadenant
CAS No.: 870070-55-6

Chemical Structure| 870070-55-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tozadenant is a selective adenosine A2A receptor antagonist with Ki values of 11.5 nM on human A2A and 6 nM on rhesus A2A, which can improve motor function in animal models of Parkinson's disease.

Synonyms: SYN115

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tozadenant

CAS No. :870070-55-6
Formula : C19H26N4O4S
M.W : 406.50
SMILES Code : COC1=CC=C(N2CCOCC2)C2=C1N=C(NC(=O)N1CCC(C)(O)CC1)S2
Synonyms :
SYN115
MDL No. :MFCD21642026
InChI Key :XNBRWUQWSKXMPW-UHFFFAOYSA-N
Pubchem ID :11618368

Safety of Tozadenant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Tozadenant

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00783276 Cocaine Dependence Early Phase 1 Completed - United States, Texas ... More >> University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 Less <<
NCT01283594 Parkinson's Disease Phase 2 Phase 3 Completed - -
NCT00605553 Parkinson's Disease Phase 2 Completed - United States, Missouri ... More >> Washington University St. Louis Saint Louis, Missouri, United States, 63110 Less <<
NCT03212313 Hepatic Impairment PHASE1 TERMINATED 2017-12-31 University of Miami, Miami, Fl... More >>orida, 33136, United States|Orlando Clinical Research Center, Orlando, Florida, 32809-3017, United States Less <<
NCT03200080 Abuse Potential Phase 1 Terminated(New Safety Informat... More >>ion) Less << - Canada, Ontario ... More >> INC Research Toronto, Inc. Toronto, Ontario, Canada, M5V 2T3 Less <<
NCT03051607 Idiopathic Parkinson Disease PHASE3 TERMINATED 2018-01-16 Barrow Neurology Clinics, St. ... More >>Joseph's Hospital and Medical Center, Dignity Health, Phoenix, Arizona, 85013, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 77215, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, 90802, United States|USC, Keck School of Medicine, Los Angeles, California, 90089, United States|SC3 Research Group, Pasadena, California, 91105, United States|JEM Research Institute, Atlantis, Florida, 33462, United States|Aventura Neurologic Associates, Aventura, Florida, 33180, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, 33486, United States|Neurology Associates, P.A., Maitland, Florida, 32751, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, 32174, United States|Parkinson's Disease Treatment Center of SW Florida, Port Charlotte, Florida, 33980, United States|Infinity Clinical Research, Sunrise, Florida, 33513, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, 96817, United States|Unity Point Health, Des Moines, Iowa, 10034, United States|Unity Point Health, Des Moines, Iowa, 50312, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|University of Kentucky, Department of Neurology, Lexington, Kentucky, 40536, United States|Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, 48322, United States|Struthers Parkinson's Center, Golden Valley, Minnesota, 55416, United States|Struthers Parkinson's Center, Golden Valley, Minnesota, 55427, United States|The Robert and John M. Bendheim Parkinson and Movement Disorders Center, New York, New York, 10029, United States|Asheville Neurology Specialists, PA, Asheville, North Carolina, 28806, United States|Raleigh Neurology Associates, Raleigh, North Carolina, 27607, United States|Movement Disorders Clinic of Oklahoma, Tulsa, Oklahoma, 74136, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, 27607, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|University of Virginia, Department of Neurology, Charlottesville, Virginia, 98034, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, 98034, United States|Premier Clinical Research, Spokane, Washington, 99202, United States|University of Wisconsin-Madison, Madison, Wisconsin, 53705, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53706, United States|Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada|The Walton Centre NHS Foundation Trust, Neuroscience Research Center, Liverpool, England, L9 7U, United Kingdom|Newcastle University Clinical Ageing Research Unit (CARU), Newcastle upon Tyne, England, NE4 5PL, United Kingdom|The Queen Elizabeth University Hospital Department of Neurology, Glasgow, Scottland, G51 4TF, United Kingdom Less <<
NCT02240290 N/A, as Healthy Volunteers Phase 1 Completed - Netherlands ... More >> Pharmaceutical Research Associates Group B.V. Zuidlaren, Netherlands Less <<
NCT02453386 Idiopathic Parkinson's Disease Phase 3 Terminated(New Safety Informat... More >>ion) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.60mL

4.92mL

2.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories